Xcout Intel
ImmunoPhotonics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to ImmunoPhotonics, Inc. among biotechnology companies — ranked by similarity to what ImmunoPhotonics, Inc. actually does, not by market-cap band.
Subscribe to see ImmunoPhotonics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About ImmunoPhotonics, Inc.
ImmunoPhotonics, Inc. is a privately owned clinical-stage biopharmaceutical and pharmaceutical manufacturing company located in St. Louis, Missouri, specializing in interventional immuno-oncology.
ImmunoPhotonics, Inc. at a glance
ImmunoPhotonics, Inc. is a biotechnology company headquartered in United States. It has raised at least $40.8M across the 7 funding rounds on record, 6 of them with a disclosed amount. Its most recent funding round raised $10.1M in July 2025. Xcout tracks 22 named people at ImmunoPhotonics, Inc., including Robert H. Arch (CEO & PRESIDENT).
ImmunoPhotonics, Inc. leadership
- Robert H. ArchCEO & PRESIDENT
- Alexander M. HurstCHIEF CORPORATE OFFICER & GENERAL COUNSEL
- Edwina Baskin-BeyCHIEF MEDICAL OFFICER
- Jonathan KnowlesCHAIRMAN
- Lu AlleruzzoCO-FOUNDER & DIRECTOR
- Wei R. ChenCO-FOUNDER, CO-INVENTOR & DIRECTOR
16 more named people on record for ImmunoPhotonics, Inc., with roles, board committees and tenure — see the full roster →
ImmunoPhotonics, Inc. funding rounds
At least $40.8M raised across the 7 rounds on record (6 with a disclosed amount). The 6 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $10.1M | — | |
| SEC Form D filing | $1.5M | — | |
| SEC Form D filing | $3.5M | — | |
| Series B | $21.4M | — | |
| Series A | $2.5M | — | |
| Series A | $1.8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 ImmunoPhotonics, Inc. competitors
Ranked by semantic similarity — how close each company is to ImmunoPhotonics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Immunomic Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2005 and headquartered in Rockville, Maryland, that develops innovative immune therapies.
Similar biotechnology company
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, with an additional office in Belgium. The company focuses on discovering and developing novel immuno-oncology therapeutics for cancer treatment.
Similar biotechnology company
BioEclipse Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in California. The company is focused on researching and developing a novel generation of targeted immunotherapies and treatments for oncology.
Similar biotechnology company
Imvax, Inc. is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, focused on developing personalized, whole-cell immunotherapies for the treatment of various cancers.
Similar biotechnology company
ImmunOs Therapeutics AG is a biotechnology company that develops treatments for cancer and inflammatory diseases by harnessing the human immune system. The company focuses on immuno-oncology and autoimmune therapies through a dedicated drug pipeline.
Similar biotechnology company
ImaginAb, Inc. is a global biotechnology company headquartered in California, with operations in Los Angeles and San Diego. It focuses on developing next-generation imaging and radiopharmaceutical products for cancer immunology.
Similar biotechnology company
Immune Design Corp. is a clinical-stage immunotherapy company with offices in Seattle, Washington, and South San Francisco, California, specializing in novel drug discovery and treatment technologies.
Biotech
ImmunityBio, Inc. is a public clinical-stage immunotherapy company headquartered in San Diego, California. As a member of the NantWorks ecosystem, it focuses on developing next-generation cancer vaccines and immunotherapies.
Similar biotechnology company
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
Biotech
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
Similar biotechnology company
iOmx Therapeutics AG is a biopharmaceutical company located in Martinsried near Munich, Germany, dedicated to discovering and developing next-generation targeted cancer immunotherapies.
Biotech
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of ImmunoPhotonics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for ImmunoPhotonics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →